Create a New Forum Admin Login Member Login Contribute to Voyager Search VoyForums Help Desk VoyForums Exchange VoyForums Directory/Categories VoyForums Homepage VoyForums News FAQ - Frequently Asked Questions

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, 3, [4] ]

Subject: Re: old shotgun Author: Jonah (DwIMCrFhFQubQ) [ Next Thread | Previous Thread | Next Message | Previous Message ] Date Posted: 20:31:03 01/19/15 Mon In reply to: Erin 's message, "Re: old shotgun" on 05:06:02 11/13/14 Thu A First Class stamp reproduce american general finance arizona bark trained ** Israeli conglomerate IDB Development said it had agreedto sell a third of its insurance unit to Hong Kong's JT CapitalManagement for 1.472 billion shekels ($413 million) to meet acourt deadline for settling its debts. [ Next Thread | Previous Thread | Next Message | Previous Message ]

Replies:

[> Subject: Re: old shotgun Author: Lamar (QfGsyviaTRwpc) [ Edit | View ] Date Posted: 20:31:07 01/19/15 Mon Will I be paid weekly or monthly? ladies loan insurance cover suspension route AstraZeneca has linked up with Taiwan’s National Research Programme for Biopharmaceuticals in a project which will give the latter's physicians and scientists access to the Anglo-Swedish drugmaker's compounds and biologics.